Tips from Other Journals
Beta Blockers as First-line Therapy for Hypertension?
FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.
FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.
Am Fam Physician. 2006 Aug 1;74(3):492-498.
Beta-blocking drugs have been the mainstay of hypertension therapy for three decades. Because recent analyses have questioned the effectiveness of atenolol (Tenormin), Lind-holm and colleagues reexamined the evidence for effectiveness of the entire class of beta blockers in hypertension.
They conducted a meta-analysis of randomized controlled clinical trials using a beta blocker as first-line therapy for primary hypertension. Eligibility was restricted to trials in which beta blockers were used in at least one half of all patients in the treatment group, and the outcomes measured included all-cause mortality, cardiovascular morbidity, or both. Studies were identified from electronic databases of systematic reviews and published reports. The analysis separated studies comparing beta blockers with placebo from those comparing beta blockers with other drugs. The outcome measures considered were stroke, myocar-dial infarction, and death. Heart failure was not included as an outcome because it was not reported in several trials.
In the seven studies (including more than 27,400 patients) comparing beta blockers with placebo or no treatment, the relative risk of stroke was reduced by 19 percent with beta blockers. The greatest reduction in stroke risk occurred in the two studies that used beta blockers in combination with other drugs, usually diuretics. Combination therapy was associated with a 45 percent reduction in stroke risk and a 43 percent reduction in mortality risk.
In the 13 eligible studies (including nearly 106,000 patients) comparing beta blockers with other antihypertensive drugs, the relative risk of stroke was 16 percent higher with beta blockers than with alternative drugs. The groups did not differ in the risk of myocardial infarction, and there was a 3 percent increase in the relative risk of overall mortality in the beta-blocker group. Subgroup analysis showed the most significant increased risk of stroke (relative risk, 26 percent) in patients treated with atenolol. Too few events occurred in patients treated with non-atenolol beta blockers to draw valid conclusions.
The authors conclude that the reduction in stroke risk associated with beta-blocker therapy is about 19 percent, or about one half of the effect commonly quoted in the medical literature. They speculate that the effectiveness of beta blockers has been overestimated because these agents are commonly prescribed in combination with thiazide diuretics. Because all antihy-pertensive drugs lower blood pressure by comparable amounts, the authors discuss mechanisms that might explain the superior effect of non-beta blockers in stroke and cardiovascular mortality. Possible explanations include effects on lipid and glucose metabolism or a differential effect on brachial and central blood pressure. They conclude that beta-blocker therapy is suboptimal and may prove more expensive than alternative therapies if the costs of the excess adverse events are taken into consideration.
Lindholm LH, et al. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. October 29, 2005;366:1545–53.
editor's note: Some commentators1 have concluded that this and other studies indicate that beta blockers should no longer be first-line therapy for primary hypertension except in certain patients (e.g., patients with hyperadrenalism). Other classes of antihy-pertensive drugs are more effective and are perceived to have additional benefits, such as prevention of diabetes. The long-term economic impact of changing the role of beta blockers is unclear. A more immediate concern is that patients may discontinue beta blockers suddenly or change precipitously to an alternative agent. These patients are thought to be at risk for rebound angina, hypertension, or even myocardial infarction. While awaiting an anticipated change in practice guidelines, physicians are urged to counsel patients not to suddenly discontinue beta blockers. Physicians also should reconsider the optimal choice of agent for each patient with hypertension.—a.d.w.
1. Beevers DG. The end of β blockers for uncomplicated hypertension?. Lancet. 2005;366:1510–2.
Copyright © 2006 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions